Medovex CEO writes letter to shareholders; highlights DenerveX System success: 6 key points

Megan Wood -   Print  |

Atlanta-based Medovex's CEO Jarrett Gorlin released a letter to its shareholders.

Here are six key points covered in the letter:


1. Medovex outlined it's achievements with the DenerveX System, which is intended to subdue facet joint syndrome pain.


2. In October 2015, Medovex hosted a DenerveX System cadaver lab at the North American Spine Society Meeting. Seventeen spine surgeons from a variety of countries participated in the lab.


3. Medovex also attended the Forum Spine Surgery of the German Spine Society, during which 150 spine surgeons watched DenerveX System demonstrations.


4. In February 2016, Germany approved new reimbursement payment coding for the DenerveX System technology, allowing hospitals and outpatient centers to receive reimbursement for using the system.


5. In April 2016, Medovex created a distribution agreement with Innosurge, allowing for DenerveX System distribution in Denmark, Sweden, Norway and Finland.


6. In June 2016, Medovex reported the DenerveX System had successfully performed a live tissue test, using Good Laboratory Practice standards.


More articles on devices:
Medline to build new distribution center; adds 100 jobs in Florida — 6 points
3D technology makes its mark in medical device industry — 3 observations
Spine Wave launches Velocity L Expandable Interbody Device & lateral system: 5 takeaways

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers